

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.:

2879-US

Charles R. Maliszewski, Richard B. Gayle, III, Virginia L. Price, and Steven D. Gimpel

Group Art Unit: 1644

Serial No: 09/835,147

Filed:

Examiner: Maher Haddad

April 13, 2001

For:

INHIBITORS OF PLATELET ACTIVATION AND RECRUITMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

JUL 0 8 2003

TECH CENTER 1600/2900

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the indicated below.

Date: Quil

## RESPONSE TO REQUIREMENT FOR ELECTION OF SPECIES

This responds to the Examiner's requirement for an election of species mailed 31 March 2003. Applicants submit herewith a petition for a two month extension of time, extending the period of response to 30 June 2003.

Applicants provisionally elect the soluble CD39 polypeptide of claim 7, having the sequence of amino acids 21-463 of SEQ ID NO:30.

Generic claims 1-6 and 25-29, and species claim 7 read upon the elected species.

**Immunex Corporation** Law Department 51 University Street Seattle, Washington 98101

Telephone: (206) 265-4079

Respectfully submitted,

Julie K. Smith, Ph.D.

Registration No. 38,619